Literature DB >> 23974301

Reliable set-up for in-loop ¹¹C-carboxylations using Grignard reactions for the preparation of [carbonyl-¹¹C]WAY-100635 and [¹¹C]-(+)-PHNO.

Christina Rami-Mark1, Johanna Ungersboeck, Daniela Haeusler, Lukas Nics, Cecile Philippe, Markus Mitterhauser, Matthaeus Willeit, Rupert Lanzenberger, Georgios Karanikas, Wolfgang Wadsak.   

Abstract

Aim of this work was the implementation of a generalized in-loop synthesis for (11)C-carboxylations and subsequent (11)C-acylations on the TRACERlab FxC Pro platform. The set-up was tested using [carbonyl-(11)C]WAY-100635 and, for the first time, [(11)C]-(+)-PHNO. Its general applicability could be demonstrated and both [carbonyl-(11)C]WAY-100635 and [(11)C]-(+)-PHNO were prepared with high reliability and satisfying outcome.
© 2013 The Authors. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Carbon-11; Grignard reaction; Loop method; [(11)C]-(+)-PHNO; [carbonyl-(11)C] WAY 100635

Year:  2013        PMID: 23974301      PMCID: PMC3842501          DOI: 10.1016/j.apradiso.2013.07.023

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


Introduction

Radiolabeling of 11C-acyl-chlorides and subsequent acylation of suitable precursor compounds are a tool for the production of carbon-11 labeled PET-tracers (Arai et al., 2009; Luthra et al., 1990; Matarrese et al., 2002; McCarron et al., 1996; Zhang et al., 2006). These carbon-11 synthons are prepared using the reaction of [11C]CO2 ([11C]carbon dioxide) and various organo-magnesium halides (so called Grignard reagents (Walborsky, 1990)) for further acylation reactions leading to demanded radiotracer compounds. One of these compounds is the well-known PET-tracer, [carbonyl-11C]WAY-100635, which is a highly potent antagonist at serotonin-1A receptor (5HT1A) (Andree et al., 2000; Pike et al., 1996). Since the implementation of Grignard reactions is a challenging task for radio-chemists, many set-ups and procedures have been reported, either using a so called “wet” reaction (Hwang et.al., 1999; Krasikova et al., 2009; Pike et al., 1996) or using an in-loop-method (Krasikova et al., 2003; Matarrese et al., 2002; McCarron et al., 1996). Comparing the published data, all procedures lead to a suitable reaction outcome for further use, but specific radioactivities achieved by loop-methods are superior to those in “wet” methods. In-loop reactions for carbon-11-labeled radioligands have been described for both 11C-methylations (Gómez et al., 2008; Wilson et al., 2000, 2009; Iwata et al. 2001) and 11C-carboxylations using Grignard reactions (Arai et al., 2009; Courtyn et al., 2001; Krasikova et al., 2003; Luthra et al., 1990; Matarrese et al., 2002; McCarron et al., 1996; Zhang et al., 2006). We previously published an in-loop set-up for the routine production of [carbonyl-11C]WAY-100635 (Wadsak et al., 2007) which is still in use in our facility in various clinical studies dealing with the (patho-)physiological distribution of serotonin 5HT1A receptor, e.g. basic neuroscience investigations (Hahn et al., 2012; Savli et al., 2012; Witte et al., 2009), studies of several psychiatric disorders including major depression (MDD) (Lanzenberger et al., 2012), anxiety disorders (Lanzenberger et al., 2007; Spindelegger et al., 2009) and temporal lobe epilepsy (Assem-Hilger et al., 2010). Many other pharmacologically interesting compounds for neurological and psychiatric pathologies could also be obtained using such a two-step synthesis route – first a Grignard reaction and a subsequent [11C]acylation. Among these compounds, especially, the dopamine D2/3 receptor agonist [11C]-(+)-PHNO ([11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol hydrochloride) is of interest. It was described as a superior PET-tracer for the fluctuations of synaptic dopamine (Narendran et al., 2006; Searle et al., 2010; Shotbolt et al., 2012; Willeit et al., 2006). The radiosynthesis of this 11C-compound was described in a challenging procedure by Wilson et al. (2005) and, most recently, by Plisson et al. (2012). The technical set-up using the proposed methods is very demanding since it includes a distillation step for the purification of the intermediate 11C-acylating agent (see Table 1).
Table 1

Comparison of reaction parameters for the synthesis of [11C]-(+)-PHNO.

SynthesisWilson et al. (2005)Plisson et al. (2012)Oya et al. (2013)Present work (2013)
Starting activity 11CO2 (EOB)~35 GBq~70 GBq~130 GBq60.7±4 GBq
11CO2 trappingLiquid N2 coolingCarbosphere trapCarbosphere trapCarbosphere trap
Grignard reactionIn-vial; EtMgBr in diethylether/THF 0.5 M/0.4 mLIn-vial; EtMgBr/THF 250 mM/0.4 mL THF, diethyletherIn-vial; EtMgBr in diethylether /THF 0.5 M/0.4 mLIn-loop; EtMgBr/THF (1M/1.5 mL)
Synthesis of acylation reagentsPhthaloyl dichloride in THF (0.5 mL, 2M)+DMF and 2,6-di-tert-butylpyridine; heated to 130 °C and distilledPhthaloyl dichloride in THF and 2,6-di-tert-butylpyridine; heated to 170 °C and distilledPhthaloyl dichloride (0.4 mL) and 2,6-di-tert-butylpyridine (0.3 mL), distillation, Ar flowSOCl2/THF (5/400 µL)
Acylation reactionTrapping −30 °C, 8 µmol HNO 50 µl THF, 50 µL diisopropylethyl-amine, 85°CTrapped −5 °C, 1–2 mg HNO 0.6 ml THF 50 µL TEA, 80 °CTrapped −5 °C, HNO in THF Diisopropylethyl-amine, 80 °C2.5 mg (+)-HNO 400 µL THF, 50 µL TEA, 80 °C
Hydration−30 °C °C, 0.6 mL 0.2N LiAlH4 in THF, 85 °C−15 °C, 0.1 mL 1M LiALH4 in THF 0.2 mL diethylether, 80 °C0 °C, LiAlH4 in THF−15 °C, 0.52 °mL LiAlH4 in THF , 80 °C
QuenchingTHF evaporation.1 mL HPLC solventTHF evaporation 1M HCl2 M HClTHF evaporation, 0.8 mL 1M HCL 0.8 mL 1M NaOH
PurificationSemi-preparative HPLC, evaporation and resolubilizationSemi-preparative HPLC, SPESemi-preparative HPLC, SPESemi-preparative HPLC, SPE
Specific activity(EOS)33–67 GBq/µmol84±37 GBq/µmol18–91 GBq/µmol140.6±71 GBq/µmol
RCY (EOS)0.26–0.44 GBq3.3±1.0 GBq1.5–4.8 GBq1.83±0.55 GBq
Synthesis time40 min35.4±1.9 min50–55 min37±2 min
Since the in-loop method for 11C-carboxylation has originally been implemented on site for the preparation of [carbonyl-11C]WAY-100635 using a Nuclear Interface C11-methylation synthesizer modifications were necessary to translate the set-up to the TRACERlab FxC Pro platform now in use. Moreover, these modifications should enable the implementation of a generalized in-loop synthesis for 11C-carboxylations (Fig. 1). Its suitability was tested in the preparation of both [11C]-(+)-PHNO and [carbonyl-11C]WAY-100635 (Fig. 2).
Fig. 1

Illustration of synthesizer set-up adapted for in-loop 11C-carboxylations.

Fig. 2

Chemical Structure of [11C]-(+)-PHNO and [carbonyl-11C]WAY 100635. ⁎ indicates the radioactive 11C atom.

Materials and methods

General

Grignard reagents were purchased from Sigma Aldrich: ethylmagnesium bromide (3.0 M in diethylether, in Sure-Seal™), cyclohexylmagnesium chloride (2.0 M in diethyl ether) and methylmagnesium bromide (3.0 M in diethylether in Sure-SealTM). Tetrahydrofurane (THF, p.a., without stabilizing agent), thionyl chloride (SOCl2, 99%) and triethylamine (TEA, 99.5%) were obtained from Sigma Aldrich (St.Louis, MO, USA). Lithium aluminum hydride (LiAlH4, 1 M in THF) was obtained from ABX (Advanced Biochemical Compounds, Radeberg, Germany). 80 cm of a polyethylene (PE) tubing (Fine Bore Polythene Tubing REF 800/100/280; ID: 0.86 mm OD: 1.52 mm, Smiths Medical International Ltd., Kent, UK) was used as “Grignard loop” material. Ascarite II, 20–30 mesh, was obtained from Thomas Scientific (Swedesboro, USA). Sterile water was purchased from Meditrade Medicare Medizinprodukte (Kufstein, Austria). Solid phase extraction (SPE) cartridges (SepPak® C18-plus) were obtained from Waters (Waters® Associates Milford, MA, USA). 0.9% saline solution from B.Braun (Melsungen, Germany), 3% saline solution from a local pharmacy (Landesapotheke Salzburg, Austria), sodium dihydrogenphosphate-monohydrate and disodiumhydrogenphosphate-dihydrate (both from Merck, Darmstadt, Germany) were used for formulation of the product. [11C]CO2 was produced in a GE PETtrace cyclotron (General Electric Medical System, Uppsala, Sweden) via the 14N(p,α)11C nuclear reaction by irradiation of a gas target (Aluminum) filled with N2 (+1% O2) (Air Liquide Austria; irradiation parameters: 16 M eV protons, 10–25 µA h). Preparations were performed on the TRACERlab™ FX C Pro synthesis platform (GE Healthcare, Uppsala, Sweden) including semi-preparative HPLC, SPE purification and product formulation. Chemicals for preparative and analytical High Pressure Liquid Chromatography (HPLC) were obtained from Merck (Darmstadt, Germany) and Sigma-Aldrich (Vienna, Austria) with at least analytical grade and used without further purification. Analytical radio-HPLC runs were performed to verify product identity, to determine radiochemical purity, and to quantify specific activity using a Merck-Hitachi LaChrom system with a UV-detector and NaI-radio detector from Berthold Technologies (Bad Wildbach, Germany).

Radiosyntheses

In-loop−C-carboxylation: 80 cm polyethylene (PE)-tubing was coiled into a loop and equipped with two Luer-fittings. Loops were coated with a mixture of one of the three respective Grignard reagents (500 µL) or diethyl ether (as negative control) in THF (1000 µL) for comparison reasons. Therefore, the respective diluted Grignard solution was pushed through the loop and completely drained by a smooth He-stream (5 mL/min). (note: Grignard reagents were purchased as solutions in diethyl ether). The inlet of the loop was connected immediately after impregnation to the line from the molecular sieve CO2 trap and the outlet to an Ascarite II trap to collect unreacted [11C]CO2. Upon delivery from the cyclotron, [11C]CO2 was transported to the hot cell and trapped on-line within the molecular sieve. Subsequently, it was released by heating the trap to 400 °C and the gas was passed to the previously impregnated loop using a smooth stream of helium (3–5 mL/min). Excess of unreacted [11C]CO2 (or not combined 11C-intermediates) was retained within the Ascarite II trap. The bound 11C-acylation synthon was swept out of the loop using a mixture of THF (400 µL) and thionyl chloride (5 µL). [Carbonyl-C]WAY-100635: Precursor compound, WAY-100634, and reference compound, WAY 100635, were obtained from ABX-Advanced Biochemical Compounds (Radeberg, Germany). Semi-preparative HPLC: column: Phenomenex® Gemini, 10 µm 110 A, 250×10 mm2; mobile phase: methanol/0.1 M ammonium formate (70/30) (v/v%) plus 3 mL TEA per liter; 8 mL/min; analytical HPLC: column: Waters® µ-Bondapak C-18 (5 µm, 300×3.9 mm2 WAT027324) mobile phase: 0.1 M ammonium formate/ACN (55/45 v/v%); 2 mL/min. Up-scaled [carbonyl-11C]WAY-100635 production was performed according to Wadsak et al. (2007) with modifications due to the implementation of a new TRACERlab™ FX C pro synthesizer. Briefly, loop was coated by pushing a cyclohexane magnesium chloride solution (0.5 mL) in THF (1 mL) through the PE-tubing equipped with Luer-fittings. Radioactivity was trapped nearly quantitatively and converted on-line to magnesium chloride cyclohexane [11C]carboxylate. Using a thionyl chloride solution (5 µL in 400 µL THF), the Grignard reaction intermediate was converted to the respective carboxylic acid chloride, swept out the loop and transferred into the reactor vial containing precursor (WAY-100634, 3.4–3.6 mg) in TEA (20 µL) and THF (50 µL). Resulting reaction mixture was heated up to 70 °C for 4 min, cooled down to room temperature and quenched with water (1 mL). Crude reaction mixture was automatically transferred and injected to the semi-preparative HPLC system triggered by a fluid detector. Product peak was collected (6–8 mL) and diluted (80 mL water) within the bulb and passed through an SPE (C-18 plus) column. After complete transfer, the column was washed with water (10 mL) and the purified product was eluted with 1.5 mL ethanol and 5 mL 0.9% saline solution. For final formulation, further 9 mL saline solution 0.9%, 1 mL saline solution 3% and 1 mL phosphate buffer (125 mM) were added, transferred to a lead shielded laminar-air-flow hot cell and sterile-filtered on-line. [C]-(+)-PHNO: Precursor compound, (+)-HNO hydrochloride, and reference compound, (+)-PHNO, were obtained from ABX-Advanced Biochemical Compounds (Radeberg, Germany). Semi-preparative HPLC: column: Phenomenex® Luna C18(2), 10 µm, 250×10 mm2; mobile phase: 25 mM PBS (pH 7.0)/acetonitrile (ACN) (60/40 v/v%); 6 mL/min); analytical HPLC: LichroCART® Lichrospher 100, RP-18 (5 µm, 4×250 mm2) with LichroCART® Lichrospher RP-18 guard column (5 µm, 4×4 mm2), mobile phase: 10 mM PBS (pH 7.0)/ACN (60/40 v/v%); 1.5 mL/min). The [11C]-(+)-PHNO-radiosynthesis is outlined in Scheme 1. The first reaction step in the synthesis sequence, the Grignard reaction, was performed on the basis of the previously described production of [carbonyl-11C]WAY-100635 adopting the loop method. In this case, the PE-loop was coated with ethyl magnesium bromide (500 µL) in THF (1000 µL) for the conversion to magnesium bromide [11C]propionate. Using thionyl chloride solution (5 µL in 400 µL THF), the built [11C]propionic acid chloride was transferred directly into the reaction vessel containing (+)-HNO (2.5 mg) suspended in TEA (50 µL) and THF (400 µL). The resulting reaction mixture was heated to 80 °C for 5 min. After cooling down to −15 °C, LiAlH4 (120 µL) in THF (400 µL) was added to the reaction intermediate (i.e. [11C]1-((4αR,10βR)-9-hydroxy-5,6-dihydro-2H-naphtho[1,2-β][1,4]oxazin-4(3 H,4αH,10βH)-yl)propan-1-one) and subsequently heated up to 80 °C for 2 min. Subsequently, THF was evaporated completely within 2 min and the reaction mixture was cooled to 45 °C. Crude [11C]-(+)-PHNO was dissolved in 1 M HCl (800 µL) and neutralized with 1 M sodium hydroxide solution (800 µL) prior to injection onto semi-preparative HPLC. The HPLC fraction containing purified [11C]-(+)-PHNO was collected (7–9 mL), diluted with water (70 mL) and passed through a C-18 Sep-Pak® plus cartridge. Further workup procedure and formulation of the final product were identical to the described [carbonyl–11C]WAY-100635 method (see above).
Scheme 1

Radiosynthesis of [11C]PHNO

Results and discussion

In-loop−C-carboxylation: 3 Grignard reagents were tested regarding the trapping of [11C]CO2 and release of the respective 11C-acylation synthon (11C-carboxylic acid chloride). Release and conversion was tested using thionyl chloride in THF for sweeping. All Grignard reagents were able to trap irradiated [11C]CO2 nearly quantitatively (Table 2). Using a mixture of THF and diethyl-ether alone (i.e. without any Grignard reagent; “negative control”) almost no trapping occurred (2.7±1.1% of initial radioactivity). The release of radioactivity revealed minor differences within the three tested Grignard reagents: [11C]propionic acid chloride and cyclohexyl [11C]carboxylic acid chloride solution could be transferred to an extent of 98.9±2%. [11C]acetic acid chloride solution contained 96.4±1.4% of the trapped radioactivity. Methyl magnesium bromide was chosen as additional Grignard reagent to test whether the described method is able to guarantee reliable outcome for further 11C-acylation synthons. Moreover, it might be useful for the development of several radiotracers planned for application in clinical trials in future.
Table 2

In-loop trapping efficiency. 80 cm PE-Loops were coated with a mixture of the respective Grignard reagents (500 µL containing ether)+THF (1000 µL). Calculated percentages of radioactivity are referred to [11C]CO2 (=100%) at EOB. Values are given as arithmetic means±SD (n≥3; corrected for decay).

Trapping into loop [%]Release of 11C-acylation synthon [%]
THF/ether2.7±1.1
Methyl magnesium bromide~10096.4±1.4
Ethyl magnesium bromide~10098.9±2
Cyclohexane magnesium chloride~10098.9±2
[Carbonyl−C]WAY-100635: Overall synthesis outcome for the modified routine-production set-up was 15.5±9.0% (3.4±2.1 GBq, n=22) (end of synthesis, EOS). The monitoring of the radioactivity during the production process (Table 3) revealed that irradiated [11C]CO2 was trapped nearly quantitatively within the impregnated loop and 98±2% (decay corrected) thereof were swept out using thionyl chloride in THF. The routine procedure, including [11C]CO2 delivery, carboxylation within the coated loop, acylation with precursor compound (WAY-100634), HPLC and SPE purification, formulation and sterile filtration, took 31±3 min in total. The final product was obtained in a total volume of 17.5 mL (containing 8.5% ethanol) as sterile solution which always met the required quality parameters (i.e. pH, osmolality, specific activity, precursor-content, radiochemical and radionuclidic purity, absence of endotoxins, sterility) for human application. Product identity, separation from precursor and specific radioactivity were determined using analytical HPLC. Retention times in the HPLC-analysis were 4.1±0.3 min (k′=1.16±0.15) for WAY-100634 and 7.0±0.5 min (k′=2.68±0.27) for [carbonyl−11C]WAY-100635. Due to the implementation of a new synthesizer module (GE TRACERlabTM FX C Pro), and thus a change in the method of [11C]CO2-trapping, as well as difficulties with the gas supplier at the time of some of the experiments a wide deviation of specific radioactivity (25–348 GBq/µmol) was observed.
Table 3

Progression of radioactivity during [11C]-(+)-PHNO synthesis and [carbonyl-11C]WAY-100635. Calculated percentages of radioactivity are referred to initially irradiated [11C]CO2 (=100%). Values are given as arithmetic means±SD (n≥8; corrected for decay).

[11C]-(+)-PHNO
[carbonyl-11C]WAY 100635
Radioactivity (%)Duration (min)EOB (min)Radioactivity (%)Duration (min)EOB (min)
Irradiation100 (60.7±4.4 GBq)100 (55.3±8.1 GBq)
Carboxylation in loop and swept into reactor98.9±2.07798.9±2.077
Acylation513412
Reduction with LiAlH490.0±15.7619
Dilution/addition of HCl59.1±9.642368.8±10.5214
Loop waste/residue in the reactor15.1±7.012411.7±6.0115
Preparative HPLC630823
SPE, formulation, sterile filtration737831
Final product8.2±4.2%37±215.5±9.0%31±3
(1.83 ±0.55 GBq)(3.4±2.1 GBq)
[C]-(+)-PHNO: In accordance to the experiences with [carbonyl-11C]WAY-100635, the irradiated [11C]CO2 was trapped within the ethyl magnesium bromide coated loop nearly quantitatively and could be released by sweeping the loop with thionyl chloride to an extent of 98±2%. During the 11C-acylation with the precursor compound, (+)-HNO, about 10% of the radioactivity was lost. Reduction of the intermediate, [11C]1-((4aR,10bR)-9-hydroxy-5,6-dihydro-2H-naphtho[1,2-b][1,4]oxazin-4(3H,4aH,10bH)-yl)propan-1-one, with LiAlH4 could be obtained in satisfying yields. Upon evaporation of the solvent THF, 59.1±9.6% of the initial radioactivity (at end of bombardement=EOB) were obtained after quenching with hydrochloric acid and neutralization with 1 M NaOH. Radiochemical incorporation yields were measured in the diluted crude mixture and 22.8±10.2% were obtained. Retention times in the preparative HPLC-purification were 3.1±0.2 min (k′=0.41±0.09) for (+)-HNO and 7.7±0.4 min (k′=2.50±0.18) for [11C]-(+)-PHNO (Fig. 3). The product peak showed high pH sensitivity regarding its retention time; therefore neutralization of the crude mixture prior to HPLC purification is mandatory. Furthermore, three unknown (more hydrophilic) radioactive side-products were observed within the preparative chromatogram of the reaction solutions and could be separated from [11C]-(+)-PHNO with retention times of 3.05±0.1 min (k′=0.39±0.05), 3.55±0.1 min (k′=0.61±0.05) and 4.70±0.2 min (k′=1.14±0.09). Similar to the results with [carbonyl-11C]WAY-100635, specific activity was determined via analytical HPLC in a range of 57–305 GBq/µmol (140.6±71 GBq/µmol). Retention times in the respective assay were 2.1±0.1 min (k′=0.31±0.06) for (+)-HNO (precursor) and 5.2±0.2 min (k′=2.25±0.13) for [11C]-(+)-PHNO. Overall synthesis outcome was 8.25±4.2% (1.83±0.55 GBq, range 1.16–3.0 GBq, n=11; end of synthesis, EOS) within 37±2 min. Time consumption is in a comparable range to previously published synthesis procedures using the distillation method for the separation of the 11C-acylating agent (Plisson et al., 2012; Wilson et al., 2005). Initially, this distillation method was used in a few syntheses but these were stopped since constantly massive contaminations were observed within the hot-cell environment. This was obviously due to the volatility of the transferred compounds and serious problems with leak tightness of the system. Using the in-loop method – and therefore low amounts of immobilized Grignard reagents – it was demonstrated that no separation of excess Grignard intermediate from the crude product was necessary.
Fig. 3

Preparative HPLC Chromatogram of [11C]PHNO and [carbonyl-11C]WAY100635.

Conclusion

The set-up of a generalized in-loop method allows the reliable 11C-carboxylation in a rapid and feasible manner. Its general applicability was demonstrated using three different Grignard compounds in the present work. Modifications and implementation of this procedure on a widely used (commercially available) synthesizer platform was successful and straight forward. Subsequent conversion of the 11C-acylating agents without intermediate purification was performed for both [carbonyl-11C]WAY-100635 and [11C]-(+)-PHNO and revealed high reliability and satisfactory outcome. In this work, we present data on the first [11C]-(+)-PHNO radiosynthesis comprising an in-loop procedure yielding 8.25±4.2% (1.83±0.55 GBq, range 1.16–3.0 GBq, n=11; EOS) within 37±2 min. The presented method might be useful also for future developments and its implementation in other PET centers could help to widen the spectrum of available 11C-radiotracers.
  22 in total

1.  Reduced serotonin-1A receptor binding in social anxiety disorder.

Authors:  Rupert R Lanzenberger; Markus Mitterhauser; Christoph Spindelegger; Wolfgang Wadsak; Nikolas Klein; Leonhard-Key Mien; Alexander Holik; Trawat Attarbaschi; Nilufar Mossaheb; Julia Sacher; Thomas Geiss-Granadia; Kurt Kletter; Siegfried Kasper; Johannes Tauscher
Journal:  Biol Psychiatry       Date:  2006-09-18       Impact factor: 13.382

2.  High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO.

Authors:  Matthäus Willeit; Nathalie Ginovart; Shitij Kapur; Sylvain Houle; Doug Hussey; Philip Seeman; Alan A Wilson
Journal:  Biol Psychiatry       Date:  2005-12-20       Impact factor: 13.382

3.  An improved one-pot procedure for the preparation of [11C-carbonyl]-WAY100635.

Authors:  D R Hwang; N R Simpson; J Montoya; J J Man; M Laruelle
Journal:  Nucl Med Biol       Date:  1999-10       Impact factor: 2.408

4.  Radiotracer synthesis from [(11)C]-iodomethane: a remarkably simple captive solvent method.

Authors:  A A Wilson; A Garcia; L Jin; S Houle
Journal:  Nucl Med Biol       Date:  2000-08       Impact factor: 2.408

5.  Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans.

Authors:  Paul Shotbolt; Andri C Tziortzi; Graham E Searle; Alessandro Colasanti; Jasper van der Aart; Sergio Abanades; Christophe Plisson; Sam R Miller; Mickael Huiban; John D Beaver; Roger N Gunn; Marc Laruelle; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2011-08-31       Impact factor: 6.200

6.  Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography.

Authors:  Alan A Wilson; Patrick McCormick; Shitij Kapur; Matthaeus Willeit; Armando Garcia; Doug Hussey; Sylvain Houle; Philip Seeman; Nathalie Ginovart
Journal:  J Med Chem       Date:  2005-06-16       Impact factor: 7.446

7.  A simple loop method for the automated preparation of (11C)raclopride from (11C)methyl triflate.

Authors:  R Iwata; C Pascali; A Bogni; Y Miyake; K Yanai; T Ido
Journal:  Appl Radiat Isot       Date:  2001-07       Impact factor: 1.513

8.  A fully automated one-pot synthesis of [carbonyl-11C]WAY-100635 for clinical PET applications.

Authors:  Raisa N Krasikova; Jan Andersson; Phong Truong; Sangram Nag; Evgeny V Shchukin; Christer Halldin
Journal:  Appl Radiat Isot       Date:  2008-07-22       Impact factor: 1.513

9.  Efficient and reproducible synthesis of [1-11C]acetyl chloride using the loop method.

Authors:  Takuya Arai; Ming-Rong Zhang; Masanao Ogawa; Toshimitsu Fukumura; Koichi Kato; Kazutoshi Suzuki
Journal:  Appl Radiat Isot       Date:  2008-10-08       Impact factor: 1.513

10.  Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET.

Authors:  R Lanzenberger; P Baldinger; A Hahn; J Ungersboeck; M Mitterhauser; D Winkler; Z Micskei; P Stein; G Karanikas; W Wadsak; S Kasper; R Frey
Journal:  Mol Psychiatry       Date:  2012-07-03       Impact factor: 15.992

View more
  8 in total

Review 1.  (11)C[double bond, length as m-dash]O bonds made easily for positron emission tomography radiopharmaceuticals.

Authors:  Benjamin H Rotstein; Steven H Liang; Michael S Placzek; Jacob M Hooker; Antony D Gee; Frédéric Dollé; Alan A Wilson; Neil Vasdev
Journal:  Chem Soc Rev       Date:  2016-08-22       Impact factor: 54.564

2.  Exploring the impact of BDNF Val66Met genotype on serotonin transporter and serotonin-1A receptor binding.

Authors:  Christoph Kraus; Pia Baldinger; Christina Rami-Mark; Gregor Gryglewski; Gregor Gryglewsky; Georg S Kranz; Daniela Haeusler; Andreas Hahn; Wolfgang Wadsak; Markus Mitterhauser; Dan Rujescu; Siegfried Kasper; Rupert Lanzenberger
Journal:  PLoS One       Date:  2014-09-04       Impact factor: 3.240

3.  On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2/3 receptor agonist radioligand study.

Authors:  Ana Weidenauer; Martin Bauer; Ulrich Sauerzopf; Lucie Bartova; Lukas Nics; Sarah Pfaff; Cecile Philippe; Neydher Berroterán-Infante; Verena Pichler; Bernhard M Meyer; Ulrich Rabl; Patrick Sezen; Paul Cumming; Thomas Stimpfl; Harald H Sitte; Rupert Lanzenberger; Nilufar Mossaheb; Alexander Zimprich; Pablo Rusjan; Georg Dorffner; Markus Mitterhauser; Marcus Hacker; Lukas Pezawas; Siegfried Kasper; Wolfgang Wadsak; Nicole Praschak-Rieder; Matthäus Willeit
Journal:  Transl Psychiatry       Date:  2020-01-08       Impact factor: 6.222

4.  Epistasis of HTR1A and BDNF risk genes alters cortical 5-HT1A receptor binding: PET results link genotype to molecular phenotype in depression.

Authors:  Alexander Kautzky; Gregory M James; Cecile Philippe; Pia Baldinger-Melich; Christoph Kraus; Georg S Kranz; Thomas Vanicek; Gregor Gryglewski; Annette M Hartmann; Andreas Hahn; Wolfgang Wadsak; Markus Mitterhauser; Dan Rujescu; Siegfried Kasper; Rupert Lanzenberger
Journal:  Transl Psychiatry       Date:  2019-01-16       Impact factor: 6.222

5.  Toward the Optimization of (+)-[11C]PHNO Synthesis: Time Reduction and Process Validation.

Authors:  Sarah Pfaff; Cécile Philippe; Lukas Nics; Neydher Berroterán-Infante; Katharina Pallitsch; Christina Rami-Mark; Ana Weidenauer; Ulrich Sauerzopf; Matthäus Willeit; Markus Mitterhauser; Marcus Hacker; Wolfgang Wadsak; Verena Pichler
Journal:  Contrast Media Mol Imaging       Date:  2019-09-30       Impact factor: 3.161

6.  3D-printed automation for optimized PET radiochemistry.

Authors:  Alejandro Amor-Coarasa; James M Kelly; John W Babich
Journal:  Sci Adv       Date:  2019-09-13       Impact factor: 14.136

7.  Association of dopamine D2/3 receptor binding potential measured using PET and [11C]-(+)-PHNO with post-mortem DRD2/3 gene expression in the human brain.

Authors:  Arkadiusz Komorowski; Ana Weidenauer; Matej Murgaš; Ulrich Sauerzopf; Wolfgang Wadsak; Markus Mitterhauser; Martin Bauer; Marcus Hacker; Nicole Praschak-Rieder; Siegfried Kasper; Rupert Lanzenberger; Matthäus Willeit
Journal:  Neuroimage       Date:  2020-08-17       Impact factor: 6.556

8.  In-loop flow [11 C]CO2 fixation and radiosynthesis of N,N'-[11 C]dibenzylurea.

Authors:  Joseph Downey; Salvatore Bongarzone; Stefan Hader; Antony D Gee
Journal:  J Labelled Comp Radiopharm       Date:  2017-12-22       Impact factor: 1.921

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.